211 related articles for article (PubMed ID: 33264072)
21. Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis.
Ademhan Tural D; Yalçın E; Emiralioglu N; Ozsezen B; Sunman B; Nayir Buyuksahin H; Guzelkas I; Dogru D; Ozcelik U; Kiper N
Pediatr Pulmonol; 2022 Jan; 57(1):142-151. PubMed ID: 34687284
[TBL] [Abstract][Full Text] [Related]
22. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
King M; Dasgupta B; Tomkiewicz RP; Brown NE
Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
[TBL] [Abstract][Full Text] [Related]
23. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis.
Guyot N; Butler MW; McNally P; Weldon S; Greene CM; Levine RL; O'Neill SJ; Taggart CC; McElvaney NG
J Biol Chem; 2008 Nov; 283(47):32377-85. PubMed ID: 18799464
[TBL] [Abstract][Full Text] [Related]
24. Alpha 1-proteinase inhibitor abrogates proteolytic and secretagogue activity of cystic fibrosis sputum.
Hansen G; Schuster A; Zubrod C; Wahn V
Respiration; 1995; 62(3):117-24. PubMed ID: 7569330
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
[TBL] [Abstract][Full Text] [Related]
26. Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change.
VanDevanter DR; Craib ML; Pasta DJ; Millar SJ; Morgan WJ; Konstan MW;
Pediatr Pulmonol; 2018 Jan; 53(1):43-49. PubMed ID: 29064184
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease.
Taylor-Cousar JL; Wiley C; Felton LA; St Clair C; Jones M; Curran-Everett D; Poch K; Nichols DP; Solomon GM; Saavedra MT; Accurso FJ; Nick JA
J Cyst Fibros; 2015 Mar; 14(2):228-36. PubMed ID: 25466700
[TBL] [Abstract][Full Text] [Related]
28. Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum.
Sun F; Tai S; Lim T; Baumann U; King M
Can Respir J; 2002; 9(6):401-6. PubMed ID: 12522485
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
[TBL] [Abstract][Full Text] [Related]
30. Effects of native and oxidation-resistant secretory leukoprotease inhibitor on cystic fibrosis sputum: inhibition of neutrophil elastase activity and of sputum-induced secretion from porcine tracheal submucosal glands.
Schuster A; Hansen G; Zubrod-Eichert C; Wahn V
Pediatr Res; 1996 Nov; 40(5):732-7. PubMed ID: 8910939
[TBL] [Abstract][Full Text] [Related]
31. Dornase alfa in early cystic fibrosis lung disease.
Robinson PJ
Pediatr Pulmonol; 2002 Sep; 34(3):237-41. PubMed ID: 12203856
[TBL] [Abstract][Full Text] [Related]
32. Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction.
Jackson PL; Xu X; Wilson L; Weathington NM; Clancy JP; Blalock JE; Gaggar A
Mol Med; 2010; 16(5-6):159-66. PubMed ID: 20111696
[TBL] [Abstract][Full Text] [Related]
33. Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum.
Bucki R; Byfield FJ; Janmey PA
Eur Respir J; 2007 Apr; 29(4):624-32. PubMed ID: 17215317
[TBL] [Abstract][Full Text] [Related]
34. DNase I acutely increases cystic fibrosis sputum elastase activity and its potential to induce lung hemorrhage in mice.
Cantin AM
Am J Respir Crit Care Med; 1998 Feb; 157(2):464-9. PubMed ID: 9476859
[TBL] [Abstract][Full Text] [Related]
35. Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum.
Tang JX; Wen Q; Bennett A; Kim B; Sheils CA; Bucki R; Janmey PA
Am J Physiol Lung Cell Mol Physiol; 2005 Oct; 289(4):L599-605. PubMed ID: 15964901
[TBL] [Abstract][Full Text] [Related]
36. A small molecule neutrophil elastase inhibitor, KRP-109, inhibits cystic fibrosis mucin degradation.
Chillappagari S; Müller C; Mahavadi P; Guenther A; Nährlich L; Rosenblum J; Rubin BK; Henke MO
J Cyst Fibros; 2016 May; 15(3):325-31. PubMed ID: 26526358
[TBL] [Abstract][Full Text] [Related]
37. The cost of simplifying treatments for cystic fibrosis: Implications of the SIMPLIFY trial.
Gold LS; Hansen RN; Mayer-Hamblett N; Nichols DP; Gifford AH; Kloster M; Goss CH; Kessler L
J Manag Care Spec Pharm; 2024 Jan; 30(1):26-33. PubMed ID: 38153868
[TBL] [Abstract][Full Text] [Related]
38. Treatment of chronic rhinosinusitis with dornase alfa in patients with cystic fibrosis: a systematic review.
Shah GB; De Keyzer L; Russell JA; Halderman A
Int Forum Allergy Rhinol; 2018 Jun; 8(6):729-736. PubMed ID: 29323796
[TBL] [Abstract][Full Text] [Related]
39. Effects of cystic fibrosis airway secretions on rat lung: role of neutrophil elastase.
Rees DD; Brain JD
Am J Physiol; 1995 Aug; 269(2 Pt 1):L195-202. PubMed ID: 7653580
[TBL] [Abstract][Full Text] [Related]
40. Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index.
Terlizzi V; Castellani C; Taccetti G; Ferrari B
Ital J Pediatr; 2022 Aug; 48(1):141. PubMed ID: 35927765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
